Combined Molecular Mismatch Approaches to Predict Immunological Events Within the First Year After Renal Transplantation
HLA · 2024-11 · 104 (5)
DOI: 10.1111/tan.15748 ↗Kurz gefasst
Fachartikel in der Zeitschrift HLA, online erschienen am 06.11.2024. Verfasst von Cäcilia Jäger und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Kidney Transplantation, Graft Rejection, Histocompatibility Testing, HLA Antigens. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Several molecular mismatch assessment approaches exist, but data on their combined use are limited. In this study, we aimed to define distinct risk groups for rejection based on the combination of three molecular mismatch assessment approaches (i.e., eplet mismatch count, the number of highly immunogenic eplets and PIRCHE‐II score) in 439 consecutive immunological standard risk transplantations. For each molecular mismatch assessment approach, ROC analyses were used to define cut‐offs for prediction of (sub) clinical rejection according to Banff 2019 classification within the first year post‐transplant as a reference. If all three scores were below the cut‐off, the patient was assigned to the low‐risk group (19% of patients); if all three scores were above the cut‐off, the patient was assigned to the high‐risk group (21% of patients). The one‐year incidence of (sub) clinical rejection was 12% in the low‐risk group and 33% in the high‐risk group ( p = 0.003). Internal validation of the assigned risk groups for prediction of other outcomes revealed a high consistency: clinical rejection (6% vs. 24%; p = 0.004), ATG‐treated rejection (1% vs. 16%; p < 0.001) and development of de novo HLA‐DSA at 5 years post‐transplant (6% vs. 25%; p = 0.003). The molecular mismatch risk group was an independent predictor for (sub) clinical rejection (high‐risk vs. low‐risk: hazard ratio 3.11 [95%‐CI 1.50–6.45]; p = 0.002). We conclude that combining molecular mismatch approaches allows us to distinguish low‐ and high‐risk groups among standard renal allograft recipients. Independent validation in other patient populations and different ethnicities is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
- PIRCHE AG, Berlin, Germany.
- Molecular Immune Regulation, Department of Biomedicine, University of Basel, Basel, Switzerland.
- HLA-Diagnostics and Immunogenetics, Department of Laboratory Medicine, University Hospital Basel, Basel, Switzerland.
- Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
ORCID-Profile: Matthias Niemann, Gideon Hönger, Stefan Schaub
Zitieren
APA
Jäger, C., Niemann, M., Hönger, G., Wehmeier, C., Hopfer, H., Menter, T., Amico, P., Dickenmann, M., & Schaub, S. (2024). Combined Molecular Mismatch Approaches to Predict Immunological Events Within the First Year After Renal Transplantation. HLA, 104(5). https://doi.org/10.1111/tan.15748
Vancouver
Jäger C, Niemann M, Hönger G, Wehmeier C, Hopfer H, Menter T, et al. Combined Molecular Mismatch Approaches to Predict Immunological Events Within the First Year After Renal Transplantation. HLA. 2024;104(5). doi:10.1111/tan.15748
BibTeX
@article{Jger2024,
author = {Jäger, Cäcilia and Niemann, Matthias and Hönger, Gideon and Wehmeier, Caroline and Hopfer, Helmut and Menter, Thomas and Amico, Patrizia and Dickenmann, Michael and Schaub, Stefan},
title = {Combined Molecular Mismatch Approaches to Predict Immunological Events Within the First Year After Renal Transplantation},
journal = {HLA},
year = {2024},
volume = {104},
number = {5},
doi = {10.1111/tan.15748}
}
EUVIMED